Zhejiang Ausun Pharmaceutical (603229.SS) Earnings Analysis
Zhejiang Ausun Pharmaceutical (603229.SS) has no confirmed upcoming earnings date. Trailing P/E 55.96.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 603229.SS next report earnings?
No confirmed upcoming earnings date is currently scheduled for 603229.SS. This page updates as the calendar is published.
603229.SS earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2025-10-31 | 0.0455 CNY | n/a | n/a | n/a |
| 2025-03-31 | 0.14 CNY | n/a | n/a | n/a |
| 2024-08-23 | 0.08112 CNY | n/a | n/a | n/a |
603229.SS valuation and analyst view
| Trailing P/E | 55.96 |
|---|---|
| Trailing EPS | 0.13093 CNY |
| Price / book | 2.60 |
| Dividend yield | 0.86% |
| Market cap | 6.49B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Zhejiang Ausun Pharmaceutical (603229.SS)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for 603229.SS. This page updates as the calendar is published.
Did 603229.SS beat earnings last quarter?
Consensus estimate data was not available for 603229.SS's 2025-10-31 report.
What is 603229.SS's current P/E ratio and EPS?
603229.SS trades at a trailing P/E of 55.96 on trailing EPS of 0.13093438848496583 CNY.
What do analysts rate 603229.SS?
603229.SS has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.